The National Institute of Allergies and Infectious Diseases is leading COVID-19 clinical trial efforts through a large-scale network, called the COVID-19 Prevention Network (CoVPN). Dr. Jim Kublin, the executive director of operations program for CoVPN, shares more about this government-funded clinical trials network for COVID-19, the importance of diversity in research, and how tech is rapidly advancing medical discoveries.
HealthCast
Season 2
Episode 1
23m listen
Ensuring Participant Diversity in COVID-19 Vaccine Trials
Modern technology has the power to overcome clinical trial participation challenges.
-
Dr. Jim Kublin Executive Director of Operation Programs CoVPN
Related Content
-
How Tech Enables Environmental Justice at EPA
The agency wants to eliminate bias and establish new tech standards to reduce greenhouse gas emissions.
39m listen -
Building Better Data Governance Across FDA
The agency is using emerging technology to tackle its data challenges.
19m listen -
Coast Guard Poised for Growth in Cyber
The service’s prevention policy chief discusses his priorities for combatting cyber incidents that could have global impacts.
23m listen -
How VA is Using Digital Services to Expand Care to Veterans
CIO Kurt DelBene says the the agency’s 2024 priorities included AI adoption, hiring and a better user experience for veterans.
30m listen
